Good point MarsC, he certainly has "skin in the game" and like all of us be looking for SP accretion. This is also why the company's performance baffles me.
Dobinson's baby was the very successful Axiron, which was a very different development path than our generics and long gone. Maybe he is not the correct chairman for a generic not branded company.
All IMO.
Add to My Watchlist
What is My Watchlist?
